JAK2 Human
Description
JAK2 is fused to a 37 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Janus Kinase 2 (JAK2) is a protein tyrosine kinase involved in specific cytokine receptor signaling pathways. It plays a crucial role in cell growth, development, differentiation, and histone modifications. JAK2 associates with the prolactin receptor and is essential for responses to gamma interferon (IFN-γ). Mice lacking active JAK2 exhibit embryonic lethality due to the absence of definitive erythropoiesis.
Repeated freezing and thawing should be avoided.
Product Science Overview
JAK2 consists of several important domains:
- FERM Domain: Located at the N-terminal, this domain is essential for the association with cytokine receptors.
- SH2 Domain: This domain binds to STAT transcription factors.
- Pseudokinase Domain (JH2): Initially thought to be inactive, this domain has been found to have catalytic activity, albeit at a lower level compared to the kinase domain.
- Tyrosine Kinase Domain (JH1): Located at the C-terminal, this domain is responsible for the kinase activity of JAK2 .
Upon cytokine binding, JAK2 undergoes autophosphorylation, which activates the kinase. This activation leads to the recruitment and phosphorylation of STAT proteins, which then translocate to the nucleus to influence gene transcription .
JAK2 is crucial for the production and regulation of blood cells from hematopoietic stem cells. It is involved in the signaling pathways of several cytokine receptors, including those for erythropoietin, thrombopoietin, and various interleukins . The JAK2/STAT pathway is essential for normal immune responses and inflammation .
Mutations in the JAK2 gene are associated with several myeloproliferative disorders, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis . The most clinically relevant mutation is V617F, which results in a valine-to-phenylalanine substitution at position 617. This mutation leads to constitutive activation of JAK2, making hematopoietic cells more sensitive to growth factors .
JAK2 is also a therapeutic target for treating excessive inflammatory responses and certain cancers. Inhibitors targeting the JAK2/STAT pathway are being developed and tested for their efficacy in treating these conditions .
Human recombinant JAK2 is produced using recombinant DNA technology, which involves inserting the JAK2 gene into an expression system, such as bacteria or mammalian cells, to produce the protein. This recombinant protein is used in research to study the function of JAK2 and its role in various signaling pathways. It is also used in drug development to screen for potential inhibitors of JAK2 activity .
